tiprankstipranks
Trending News
More News >
Ampio Pharmaceuticals (AMPE)
OTHER OTC:AMPE
US Market

Ampio Pharmaceuticals (AMPE) Price & Analysis

Compare
507 Followers

AMPE Stock Chart & Stats

$0.26
$0.00(0.00%)
At close: 4:00 PM EST
$0.26
$0.00(0.00%)

Ampio Pharmaceuticals News

AMPE FAQ

What was Ampio Pharmaceuticals’s price range in the past 12 months?
Ampio Pharmaceuticals lowest stock price was <$0.01 and its highest was $0.26 in the past 12 months.
    What is Ampio Pharmaceuticals’s market cap?
    Ampio Pharmaceuticals’s market cap is $289.69K.
      When is Ampio Pharmaceuticals’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Ampio Pharmaceuticals’s earnings last quarter?
      Currently, no data Available
      Is Ampio Pharmaceuticals overvalued?
      According to Wall Street analysts Ampio Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Ampio Pharmaceuticals pay dividends?
        Ampio Pharmaceuticals does not currently pay dividends.
        What is Ampio Pharmaceuticals’s EPS estimate?
        Ampio Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Ampio Pharmaceuticals have?
        Ampio Pharmaceuticals has 1,135,358 shares outstanding.
          What happened to Ampio Pharmaceuticals’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Ampio Pharmaceuticals?
          Currently, no hedge funds are holding shares in AMPE
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Ampio Pharmaceuticals

            Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

            Ampio Pharmaceuticals (AMPE) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Scinai Immunotherapeutics
            Indaptus Therapeutics
            PharmaCyte Biotech
            Aditxt
            Dermata Therapeutics

            Ownership Overview

            0.04%99.96%
            Insiders
            Mutual Funds
            0.04% Other Institutional Investors
            99.96% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks